Entries by Administrator

From SXSW ’24: the power of co-creation in cultivating authenticity

At this year’s SXSW, amid the whirlwind of tech and culture, a clear yearning pulsed through its presentations and panels: a quest for authenticity, humanity, and a raw, unfiltered sense of realness. This wasn’t just a fleeting theme, but the core of what people are seeking today — in life, in technology, and yes, with brands. The following are a few key observations as a brand and design leader from the floor.

Today’s market access agency: 8 things every market access marketer should know

Market access emerged as a crucial commercial function at pharmaceutical manufacturers a little over 20 years ago, followed closely by the creation of specialized market access agencies. With so much changing over the last two decades, the time is right to take a fresh look at how market access agencies support manufacturers today to ensure that expectations are aligned and that unrealized potential doesn’t negatively impact brands.

Decoding health: transforming 80 percent of unstructured data into insights with NLP

Artificial intelligence (AI) surely stands at the forefront of one of the most transformative periods in the pharmaceutical industry. Its rapid drug discovery capabilities and potential for personalized patient care mark AI as a revolutionary influence in reshaping the pharmaceutical industry. Central to this transformation is natural language processing (NLP).

Opill’s OTC launch will pave way for more oral contraceptives to become available in United States

An unmet need in the contraceptive field is availability and access for patients. Almost half of the 6.1 million pregnancies in the United States annually are unintended, so the approval of Opill to be sold over the counter without a prescription allows increased accessibility, promoting timely use and reducing barriers to family planning, according to GlobalData.

Top patient safety concerns of 2024

Challenges transitioning new clinicians from academic training to professional practice tops ECRI’s 2024 list of top 10 patient safety concerns for 2024 released by one of the nation’s largest patient safety organizations. ECRI researchers compiled the report by drawing on evidence-based research, data, and expert insights.

Opdivo to face direct competition with Keytruda and Padcev combination in bladder cancer space

Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma. With this approval, Opdivo positions itself to compete with Merck & Co’s immune checkpoint inhibitor Keytruda in combination with Astellas and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate, according to GlobalData.